Cybin (TSE:CYBN) has released an update.
Cybin has launched a pivotal Phase 3 program named PARADIGM to evaluate CYB003 as a treatment for Major Depressive Disorder, involving multiple studies across the U.S. and Europe. The company also reported a strong cash position with C$154.3 million as of September 30, 2024, highlighting its financial readiness for these trials.
For further insights into TSE:CYBN stock, check out TipRanks’ Stock Analysis page.
